tailieunhanh - Báo cáo hóa học: " The status of clinical trials: Cause for concern"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: The status of clinical trials: Cause for concern | Nussenblatt and Meinert Journal of Translational Medicine 2010 8 65 http content 8 1 65 JOURNAL OF TRANSLATIONAL MEDICINE COMMENTARY Open Access The status of clinical trials Cause for concern Robert B Nussenblatt 1 and Curtis L Meinert2 Abstract Background Americans see clinical research as important with over 15 million American residents participating in NIH-sponsored studies in 2008 and growing yearly. Methods Documents reporting NIH supported Clinical Research projects were reviewed. Results When compared with other studies the number of interventional Phase III and Phase IV trials have decreased from 20 to from 1994-2008. Conclusions This finding most likely has occurred for several reasons. One reason is that the physician lacks an infrastructure for designing and carrying out trials. This lack is because of an absence of a coordinated effort to train clinical trialists. It is clear that the Nation needs a more purposeful approach to developing and maintaining the infrastructure for designing and conducting clinical trials. Building it de novo trial by trial is profoundly inefficient to say nothing about time consuming and error prone. Introduction Scientific advances have been extraordinary in the last 50 years. We have seen areas of basic scientific research burgeon with the hope that they will soon translate into newer and more effective ways to treat or prevent human disease. As an offshoot of these advances new therapeutic agents procedures and devices have appeared. The pharmaceutical industry has experienced decades of growth and success. It has been estimated that in 2004 over 30 billion dollars was spent on research and development in the United States by members of the Pharmaceutical Research and Manufacturers of America 1 It is clear that the American public sees the development of new treatments as important. We have seen a steady increase in participation by residents of the United States in clinical studies. .